All In Biotech

Drug Trial Radar · NCT06547164

A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female Participants

A Phase I, Open-label, 2 Part, Fixed Sequence Study to Assess the Effect of Co-administration of Camizestrant (AZD9833) on the Pharmacokinetics of Midazolam Exposure (CYP3A4/5 Substrate) and of Carbamazepine (CYP3A4/5 Inducer) on Camizestrant Exposure in Healthy Post Menopausal Female Participants

Last checked: Nov 20, 2026Latest source record: Sep 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Aug 27, 2024

Primary completion

Aug 20, 2025

Study completion Aug 20, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Aug 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 50 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will be conducted in order to determine the effect of repeated oral doses of camizestrant on the pharmacokinetics (PK) of midazolam and to determine the effect of repeated oral titrated doses of carbamazepine on the PK of camizestrant in healthy post-menopausal female participants.

Conditions

  • Healthy Participants

Interventions

  • MidazolamDrug

    Midazolam will be administered orally.

  • CamizestrantDrug

    Camizestrant will be administered orally.

  • CarbamazepineDrug

    Carbamazepine will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Area under concentration-time curve from time 0 to infinity (AUCinf) of midazolamTime frame: Period 1 (Day 1) and Period 3 (Day 7 to Day 8)
  2. Part A: Area under concentrationcurve from time 0 to the last quantifiable concentration (AUClast) of midazolamTime frame: Period 1 (Day 1) and Period 3 (Day 7 to Day 8)
  3. Part A: Maximum observed plasma (peak) drug concentration (Cmax) of midazolamTime frame: Period 1 (Day 1) and Period 3 (Day 7 to Day 8)
  4. Part B: Area under concentration-time curve from time 0 to infinity (AUCinf) of camizestrantTime frame: Period 1 (Day 1 to Day 4), Period 2 (Day 22 to Day 25)
  5. Part B: Area under concentrationcurve from time 0 to the last quantifiable concentration (AUClast) of camizestrantTime frame: Period 1 (Day 1 to Day 4), Period 2 (Day 22 to Day 25)
  6. Part B: Maximum observed plasma (peak) drug concentration (Cmax) of camizestrantTime frame: Period 1 (Day 1 to Day 4), Period 2 (Day 22 to Day 25)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Harrow, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.